口腔矫治器与持续气道正压通气比较效果:前瞻性非随机非劣效性研究
MAD依从性更高,但序贯非随机设计限制因果推断。
要点
- MAD作为一线治疗在中重度OSA中MDA非劣于CPAP。
- 51%患者偏好MAD,42%偏好CPAP。
核心结论
- MAD治疗在中重度OSA患者中达到与CPAP非劣的临床效果,主要归因于更高依从性。
研究设计与样本
- 主要结局为平均疾病缓解率(MDA),采用改良意向性治疗分析。
主要发现
- 51%患者偏好MAD,42%偏好CPAP。
关键数值与推荐
- MDA非劣效性界值未在原文中报告。
临床怎么用
- 对于CPAP不耐受的中重度OSA患者,MAD可作为有效的替代治疗选择。
- 临床决策时可考虑患者偏好,约半数患者更倾向MAD。
局限性
- 序贯非随机设计无法区分治疗效果与顺序或周期效应。
- MDA未针对患者重要结局进行验证,因此不能确立临床非劣效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Continuous positive airway pressure (CPAP) is the first‑line treatment for moderate-to-severe obstructive sleep apnea (OSA), while mandibular advancement devices (MAD) are an established alternative for CPAP-intolerant patients. Differences in efficacy and adherence may affect overall clinical effectiveness. OBJECTIVES: This prospective non-randomized study (First Line Obstructive Sleep Apnea Treatment (FLOSAT)) evaluated the clinical effectiveness of MAD therapy as first-line treatment option compared to second-line CPAP therapy. METHODS: Moderate-to-severe OSA patients received three months of MAD therapy, followed by a wash-out period and three months of CPAP therapy. The primary outcome was mean disease alleviation (MDA), a measure combining efficacy and adherence, analyzed using a modified intention-to-treat approach. MEASUREMENT AND MAIN RESULTS: Ninety-four patients (86% male, age: 52±12 years, body mass index: 28·1±3·4 kg/m2) were included. The averaged individual MDA was 49·9±26·1% with MAD and 49·1±34·5% with CPAP, demonstrating non-inferiority of MAD compared to CPAP (p = 0·4). The apnea/hypopnea index (AHI) decreased significantly from 24·2(18·1; 32·3)/h at baseline to 8·4(5·4; 12·9)/h with MAD and to 4·1(2·2; 11·5)/h with CPAP (both p < 0·001). Nightly adherence was significantly higher with MAD (6·7(5·2;7·3) hours/night) than with CPAP (5·4(2·0;6·5); p < 0·05). In this study, 51% of patients preferred MAD compared to 42% for CPAP. CONCLUSIONS: MAD therapy achieved good efficacy and high adherence, resulting in non-inferior effectiveness compared to CPAP. However, the sequential, non-randomized design limits interpretation because treatment effects cannot be separated from potential order or period effects. Furthermore, MDA has not been validated against patient-important outcomes and therefore does not establish clinical non-inferiority.
引用
- Dieltjens M, Engelen S, Azarbarzin A, et al. Comparative effectiveness of oral appliances and continuous positive airway pressure: a prospective non-randomized study using a non-inferiority framework. Am J Respir Crit Care Med. 2026. PMID: 42475493. doi:10.1093/ajrccm/aamag388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。